Titan Pharmaceuticals, Inc .

TITAN PHARMACEUTICALS ADDS PRONEURA IMPLANT

FOR HYPOTHYROIDISM TO PRODUCT DEVELOPMENT PIPELINE

SAN FRANCISCO, CA - Nov. 16, 2015 - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a specialty pharmaceutical company

developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura long-term, continuous

drug delivery technology, announced today that it has added an implantable triiodothyronine (T3) product for the treatment of hypothyroidism

to its product development pipeline. ProNeura-T3 could potentially offer significant advantages over once-daily oral delivery for

patients who need T3 in their treatment regimen.

Hypothyroidism is a disease affecting about 15 million Americans,

mostly women. Symptoms include chronic fatigue, weight gain and obesity, dry skin, impaired mental activity, and depression. The

majority of patients are diagnosed with standard blood tests and receive treatment typically consisting of synthetic prohormone

thyroxine (T4) given as a once-daily oral medication (Synthroid , Levoxyl , generics), which in turn is converted in the

body to the active T3. Based upon symptoms and blood tests it is estimated that as many as 15-20 percent of hypothyroid patients

are not adequately treated with this therapy, resulting in a persistent deficiency in the primary active form of thyroid hormone,

T3, and physicians typically add an oral T3 regimen to the treatment of these patients

synthetic T3 (Cytomel ) is an effective medication for hypothyroidism but can come with potential side effects such as headache,

nervousness, irritability, sweating, and cardiac arrhythmias, which are caused by the peak-and-trough blood-level fluctuations

of T3 associated with standard oral delivery," said Titan Executive Vice President and Chief Development Officer Kate Beebe,

Ph.D. "Continuous delivery of T3 by the oral or parenteral route is highly desirable, but has been difficult to achieve

because of the unique solubility characteristics of the compound. Thus, an implantable T3 product utilizing the ProNeura platform

that more closely replicates normal thyroid physiology and avoids the unwanted side effects associated with the current pulsatile-release

oral formulation could benefit patients and serve a great, unmet medical need."

"I am very pleased with our progress in the T3 implant

formulation development, and look forward to providing further updates as we advance towards regulatory discussions for this potential

product candidate," said Titan President Sunil Bhonsle. "The development of ProNeura for hypothyroidism could present

a significant market opportunity."

Titan's ProNeura drug delivery technology is being developed

for select chronic disease for which the low dose, continuous delivery of medication could offer health and safety benefits over

oral delivery. The company's lead product candidate, Probuphine , is being developed for the long-term maintenance treatment

of opioid addiction. The U.S. Food and Drug Administration has accepted for review a New Drug Application (NDA) for Probuphine

and has set an action date of Feb. 27, 2016 on the NDA. Titan is also developing a ProNeura implant containing ropinirole, a dopamine

agonist, for the treatment of Parkinson's disease and expects to commence clinical testing of this product candidate by the end

the ProNeura Long-term Drug Delivery Platform

ProNeura is Titan's proprietary, long-term drug delivery platform utilized in the development of products for the treatment

of select chronic conditions that may benefit from the delivery of continuous, non-fluctuating levels of certain medications over

an extended period of six months to a year. ProNeura consists of a small, solid rod made from a mixture of ethylene-vinyl acetate

("EVA") and a drug substance. The resulting product is a solid matrix that is placed subdermally, normally in the

inner part of the upper arm, during a simple office procedure, and is removed in a similar manner at the end of treatment. The

drug substance is released continuously through the process of dissolution, resulting in a stable, non-fluctuating blood level

similar to that seen with intravenous administration. These long-term, linear-release characteristics are medically desirable

to avoid the peak and trough swings from oral dosing that pose problems in the current treatments for many diseases, especially

diseases of the central nervous system. Titan has issued patents as well as patent applications covering the use of the ProNeura

long-term drug delivery platform for the formulation of specific products for the treatment of certain chronic diseases, such

as opioid dependence, Parkinson's disease, and others.

About Titan Pharmaceuticals

Titan Pharmaceuticals Inc. (NASDAQ: TTNP), based in South San

Francisco, CA, is a specialty pharmaceutical company developing proprietary therapeutics primarily for the treatment of serious

medical disorders. The company's lead product candidate is Probuphine , a novel and long-acting formulation of buprenorphine

for the long-term maintenance treatment of opioid dependence. Probuphine employs Titan's proprietary drug delivery system

ProNeura , which is capable of delivering sustained, consistent levels of medication for three months or longer. Titan has

granted North American commercial rights for Probuphine to Braeburn Pharmaceuticals. If approved, Probuphine would be the first

and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for

six months following a single procedure. The ProNeura technology has the potential to be used in developing products for treating

other chronic conditions, such as Parkinson's disease, where maintaining consistent blood levels of a dopamine agonist may

benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com.

This press release may contain "forward-looking statements"

within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements

include, but are not limited to, any statements relating to our product development programs and any other statements that are

not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results,

financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations

include those risks and uncertainties relating to the regulatory approval process, the development, testing, production and marketing

of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly

disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained

herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement

is based, except as required by law.

Titan Pharmaceuticals, Inc.:

Sunil Bhonsle, President